Skip to Content


Active Substance: daclizumab
Common Name: daclizumab
ATC Code: L04AA08
Marketing Authorisation Holder: Roche Registration Ltd.
Active Substance: daclizumab
Status: Withdrawn
Authorisation Date: 1999-02-26
Therapeutic Area: Kidney Transplantation Graft Rejection
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

The marketing authorisation for Zenapax has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.